Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6362)
All Articles published online
|
Publishing Process of This Article
|
Jul 21, 2016 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Azzariti A, Porcelli L, Brunetti O, Del Re M, Longo V, Nardulli P, Signorile M, Xu JM, Calabrese A, Quatrale AE, Maiello E, Lorusso V, Silvestris N. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. World J Gastroenterol 2016; 22(27): 6287-6295 [PMID: 27468218 DOI: 10.3748/wjg.v22.i27.6287] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i27/6287.htm |
| Number | Citing Articles |
| 1 |
Marine Jary, Reyhan Hasanova, Angélique Vienot, Kamal Asgarov, Romain Loyon, Charline Tirole, Adeline Bouard, Emeline Orillard, Elodie Klajer, Stefano Kim, Julien Viot, Elise Colle, Olivier Adotevi, Olivier Bouché, Thierry Lecomte, Christophe Borg, Jean P. Feugeas. Molecular description of ANGPT2 associated colorectal carcinoma. International Journal of Cancer 2020; 147(7): 2007 doi: 10.1002/ijc.32993
|
| 2 |
Rahmawati Minhajat, Sahyuddin Saleh, Tutik Harjianti, Andi Fachruddin Benyamin, A. M. Luthfi Parewangi, Syakib Bakri. Profiles of Endoglin and Vascular Endothelial Growth Factor Based on Staging and Histological Grading of Colorectal Cancer and Their Relationship with Bevacizumab Therapy. Journal of Coloproctology 2021; 41(02): 156 doi: 10.1055/s-0041-1724065
|
| 3 |
Oronzo Brunetti, Angela Calabrese, Loredana Palermo, Antonio Giovanni Solimando, Antonella Argentiero. Long‐term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review. Clinical Case Reports 2019; 7(12): 2379 doi: 10.1002/ccr3.2496
|
| 4 |
Tetsuo Mashima, Takeru Wakatsuki, Naomi Kawata, Myung-Kyu Jang, Akiko Nagamori, Haruka Yoshida, Kenichi Nakamura, Toshiro Migita, Hiroyuki Seimiya, Kensei Yamaguchi. Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-94584-9
|
| 5 |
Massimo Gion, Chiara Trevisiol, Aline S. C. Fabricio. Clinical and Laboratory Medicine Textbook. 2023; : 455 doi: 10.1007/978-3-031-24958-7_33
|
| 6 |
Manuel Hidalgo, Maria Martinez-Garcia, Christophe Le Tourneau, Christophe Massard, Elena Garralda, Valentina Boni, Alvaro Taus, Joan Albanell, Marie-Paule Sablin, Marie Alt, Ratislav Bahleda, Andrea Varga, Christophe Boetsch, Izolda Franjkovic, Florian Heil, Angelika Lahr, Katharina Lechner, Anthony Morel, Tapan Nayak, Simona Rossomanno, Kevin Smart, Kay Stubenrauch, Oliver Krieter. First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research 2018; 24(7): 1536 doi: 10.1158/1078-0432.CCR-17-1588
|
| 7 |
Apostolos Papachristos, Gregory B. Sivolapenko. Pharmacogenomics, Pharmacokinetics and Circulating Proteins As Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review. Journal of Personalized Medicine 2020; 10(3): 79 doi: 10.3390/jpm10030079
|
| 8 |
Farideh Ghalamfarsa, Seyyed Hossein Khatami, Omid Vakili, Mortaza Taheri-Anganeh, Amir Tajbakhsh, Amir Savardashtaki, Yousef Fazli, Leila Rezaei Uonaki, Zahra Shabaninejad, Ahmad Movahedpour, Ghasem Ghalamfarsa. Bispecific antibodies in colorectal cancer therapy: recent insights and emerging concepts. Immunotherapy 2021; 13(16): 1355 doi: 10.2217/imt-2021-0107
|